SRPT Quote, Financials, Valuation and Earnings

Arrowhead Pharmaceuticals, Inc. has a net margin of -45.06% compared to Sarepta Therapeutics, Inc.'s net margin of 10.7%. Sarepta Therapeutics, Inc.'s return on equity of -20.67% beat Arrowhead Pharmaceuticals, Inc.'s return on equity of 50.21%.

Sarepta Therapeutics, Inc. has a consensus price target of $21.43, signalling upside risk potential of 23.19%. On the other hand Arrowhead Pharmaceuticals, Inc. has an analysts' consensus of $81.67 which suggests that it could grow by 30.92%. Given that Arrowhead Pharmaceuticals, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe Arrowhead Pharmaceuticals, Inc. is more attractive than Sarepta Therapeutics, Inc..

Sarepta Therapeutics, Inc. has a beta of 0.393, which suggesting that the stock is 60.731% less volatile than S&P 500. In comparison Arrowhead Pharmaceuticals, Inc. has a beta of 1.213, suggesting its more volatile than the S&P 500 by 21.339%.

Sarepta Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arrowhead Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics, Inc. pays -- of its earnings as a dividend. Arrowhead Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Sarepta Therapeutics, Inc. quarterly revenues are $399.4M, which are larger than Arrowhead Pharmaceuticals, Inc. quarterly revenues of $264M. Sarepta Therapeutics, Inc.'s net income of -$179.9M is lower than Arrowhead Pharmaceuticals, Inc.'s net income of $28.2M. Notably, Sarepta Therapeutics, Inc.'s price-to-earnings ratio is 20.50x while Arrowhead Pharmaceuticals, Inc.'s PE ratio is 40.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics, Inc. is 0.74x versus 7.86x for Arrowhead Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Keros Therapeutics, Inc. has a net margin of -45.06% compared to Sarepta Therapeutics, Inc.'s net margin of -51.05%. Sarepta Therapeutics, Inc.'s return on equity of -20.67% beat Keros Therapeutics, Inc.'s return on equity of 9.94%.

Sarepta Therapeutics, Inc. has a consensus price target of $21.43, signalling upside risk potential of 23.19%. On the other hand Keros Therapeutics, Inc. has an analysts' consensus of $22.88 which suggests that it could grow by 37.72%. Given that Keros Therapeutics, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe Keros Therapeutics, Inc. is more attractive than Sarepta Therapeutics, Inc..

Sarepta Therapeutics, Inc. has a beta of 0.393, which suggesting that the stock is 60.731% less volatile than S&P 500. In comparison Keros Therapeutics, Inc. has a beta of 0.857, suggesting its less volatile than the S&P 500 by 14.332%.

Sarepta Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Keros Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics, Inc. pays -- of its earnings as a dividend. Keros Therapeutics, Inc. pays out -- of its earnings as a dividend.

Sarepta Therapeutics, Inc. quarterly revenues are $399.4M, which are larger than Keros Therapeutics, Inc. quarterly revenues of $14.3M. Sarepta Therapeutics, Inc.'s net income of -$179.9M is lower than Keros Therapeutics, Inc.'s net income of -$7.3M. Notably, Sarepta Therapeutics, Inc.'s price-to-earnings ratio is 20.50x while Keros Therapeutics, Inc.'s PE ratio is 10.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics, Inc. is 0.74x versus 2.74x for Keros Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -45.06% compared to Sarepta Therapeutics, Inc.'s net margin of 18.06%. Sarepta Therapeutics, Inc.'s return on equity of -20.67% beat Merck & Co., Inc.'s return on equity of 39.63%.

Sarepta Therapeutics, Inc. has a consensus price target of $21.43, signalling upside risk potential of 23.19%. On the other hand Merck & Co., Inc. has an analysts' consensus of $123.54 which suggests that it could grow by 3.61%. Given that Sarepta Therapeutics, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Sarepta Therapeutics, Inc. is more attractive than Merck & Co., Inc..

Sarepta Therapeutics, Inc. has a beta of 0.393, which suggesting that the stock is 60.731% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.280, suggesting its less volatile than the S&P 500 by 72.042%.

Sarepta Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.75% to investors and pays a quarterly dividend of $0.85 per share. Sarepta Therapeutics, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sarepta Therapeutics, Inc. quarterly revenues are $399.4M, which are smaller than Merck & Co., Inc. quarterly revenues of $16.4B. Sarepta Therapeutics, Inc.'s net income of -$179.9M is lower than Merck & Co., Inc.'s net income of $3B. Notably, Sarepta Therapeutics, Inc.'s price-to-earnings ratio is 20.50x while Merck & Co., Inc.'s PE ratio is 16.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics, Inc. is 0.74x versus 4.60x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -45.06% compared to Sarepta Therapeutics, Inc.'s net margin of -9.34%. Sarepta Therapeutics, Inc.'s return on equity of -20.67% beat Pfizer Inc.'s return on equity of 10.84%.

Sarepta Therapeutics, Inc. has a consensus price target of $21.43, signalling upside risk potential of 23.19%. On the other hand Pfizer Inc. has an analysts' consensus of $28.63 which suggests that it could grow by 4.22%. Given that Sarepta Therapeutics, Inc. has higher upside potential than Pfizer Inc., analysts believe Sarepta Therapeutics, Inc. is more attractive than Pfizer Inc..

Sarepta Therapeutics, Inc. has a beta of 0.393, which suggesting that the stock is 60.731% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.751%.

Sarepta Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.26% to investors and pays a quarterly dividend of $0.43 per share. Sarepta Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.47% of its earnings as a dividend.

Sarepta Therapeutics, Inc. quarterly revenues are $399.4M, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. Sarepta Therapeutics, Inc.'s net income of -$179.9M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, Sarepta Therapeutics, Inc.'s price-to-earnings ratio is 20.50x while Pfizer Inc.'s PE ratio is 20.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics, Inc. is 0.74x versus 2.50x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.